Michelle Mellion | Chief Medical Officer
EveryONE Medicines

Michelle L. Mellion, MD earned her undergraduate degree with honors in molecular biology from Colgate University and her medical degree from Wake Forest University School of Medicine. She completed her internship in internal medicine, residency in neurology, and fellowship in clinical neurophysiology at Brown University. Dr. Mellion served in the neurology faculty at the Warren Alpert Medical School of Brown University for over a decade. During her tenure, she led grant-funded research on various neuropathies, directed both the clinical neurophysiology fellowship and the neurology residency program, and provided care at the MDA neuromuscular clinic as well as her own general neurology practice. She also spearheaded clinical research supporting the development of a novel therapy for myasthenia gravis. Transitioning from academia to industry, Dr. Mellion joined Biogen, where she contributed to the remyelination program and the development of novel biomarkers. She later co-led the pain program at Vertex Pharmaceuticals and subsequently led the development of a novel therapy for facioscapulohumeral muscular dystrophy (FSHD).  She has also overseen the development of enhanced delivery oligonucleotide therapeutics for rare neuromuscular diseases. Currently, Dr. Mellion is the Chief Medical Officer at EveryONE Medicines, where she brings her expertise to the development of individualized medicines for ultra-rare diseases. Even after her transition to industry, she has remained active in clinical care, serving in the MDA clinic at Brown and later in the pediatric neurology clinic affiliated with Tufts University. She continues to contribute to the FSHD community through her work with the FSHD Society. Dr. Mellion’s academic and industry research has led to numerous original publications in top-tier journals.